Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.
Phase:
Phase 1
Details
Lead Sponsor:
Kaneq Bioscience Limited